The events that followed 11 September 2001 brought to companies like Human Genome Sciences, Inc. and Acambis PLC (subsequently acquired by GSK plcand Sanofi, respectively), revenues and defensive investment attributes from their products to treat anthrax and smallpox, respectively. Following, thankfully, just 17 anthrax and no smallpox cases, their bioterrorism premiums and investors’ attention waned, even though both companies were left with residual stockpiling contracts. At least the raft of small biotech companies like NanoViricides, Inc. that have recently announced monkeypox product aspirations to huge stock price gains will know what is in store for them.
Stock Watch: Pfizer’s Second-Quarter Pandemic And Base Businesses Diverge
Pfizer’s Continued COVID-19 Revenue Streams Appear Discounted
Pfizer recorded the largest quarterly sales in its history as its COVID-19 franchise easily outweighed the currency issues that are challenging other companies. But expectations for a quick end to the pandemic have wiped these gains from Pfizer’s stock price.
More from Stock Watch
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.